scispace - formally typeset
T

Toshihiro Hama

Researcher at Japanese Foundation for Cancer Research

Publications -  43
Citations -  458

Toshihiro Hama is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Regorafenib & Medicine. The author has an hindex of 9, co-authored 39 publications receiving 353 citations.

Papers
More filters
Journal ArticleDOI

Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion.

TL;DR: Results suggest that paclitaxel treatment increases TRPV1 expression in DRG neurons and may contribute to functional peripheral neuropathic pain.
Journal ArticleDOI

Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan

TL;DR: A multicenter field survey of environmental contamination and exposure of healthcare professionals to anticancer drugs were performed and CP was detected in 90 samples obtained from 23 subjects, indicating the amount of exposure was greatly different among the facilities.
Journal ArticleDOI

Paclitaxel Increases High Voltage–Dependent Calcium Channel Current in Dorsal Root Ganglion Neurons of the Rat

TL;DR: Investigation of the effects of paclitaxel on the voltage-dependent calcium channel (VDCC) current in rat dorsal root ganglion (DRG) neurons using the whole-cell patch clamp technique found that pac litaxel treatment increases the VDCC current in small- and medium-diameter DRG neurons and upregulates Ca(v)α₂δ-1.
Journal ArticleDOI

Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer.

TL;DR: When and how often PN occurs in association with paclitaxel plus carboplatin (PC therapy), a regimen used to treat non-small cell lung cancer, and factors that exacerbate this condition are determined.
Journal ArticleDOI

Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.

TL;DR: Development of irAEs was associated with survival outcome of pembrolizumab treatment in patients with advanced urothelial cancer, and risk factors for exacerbation ofirAEs were positively associated with lymphocyte count at baseline (>2,000/µL).